Atlas Trials

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Clinical trial NCT03724747 · COMPLETED

Trial details

NCT number
NCT03724747
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Start date
2018-12-18
Primary completion
2022-08-25
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.